---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-056656"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:34:14.628948+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q1 2026: Revenue $107M (+159% YoY); GAAP EPS $0.25 from -$0.23; LINZESS sales $273M (+97%)

## Summary
- GAAP net income $41M ($0.25 basic EPS) vs loss $37M ($0.23 loss) in Q1 2025.
- LINZESS U.S. net sales $273M, up 97% YoY; 5% EUTRx demand growth.
- Adjusted EBITDA $77M vs negative $4.7M a year ago.
- Maintains full-year 2026 guidance; on track to start apraglutide Phase 3 trial in Q2 2026.
- sNDA for LINZESS in pediatric FC (2-5yrs) accepted with priority review; PDUFA May 24.

## SEC filing metadata
- accession: 0001104659-26-056656
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465926056656/0001104659-26-056656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465926056656/tm267094d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-056656
- JSON: https://secwatch.observer/filing/0001104659-26-056656.json
- Plain text: https://secwatch.observer/filing/0001104659-26-056656.txt

## Source-grounded claims
- claim_id: fa46553c344aa5d5c191944356df9cff3138a9fc
  claim: IRONWOOD PHARMACEUTICALS INC reported first quarter 2026 results: revenue $ 106,506, net income 40,773, EPS 0.25. Guidance reaffirmed.
  evidence_excerpt: First Quarter 2026 Financial Highlights 1 (in thousands, except for per share amounts) Q1 2026 Q1 2025 Total revenue $ 106,506 $ 41,143 Total costs and expenses 33,933 70,251 GAAP net income (loss) 40,773 (37,386 ) GAAP net income (loss) – per share basic 0.25 (0.23 ) GAAP net income (loss) – per share diluted 0.24 (0.23 ) Adjusted EBITDA 2 76,671 (4,742 ) Non-GAAP net income (loss) 40,945 (23,228 ) Non-GAAP net income (loss) per share – basic 0.25 (0.14 ) Non-GAAP net income (loss) per share – diluted 0.24 (0.14 )
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465926056656/0001104659-26-056656-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.